Preclinical imaging platform in 2013
In 2012, the CGFL preclinical imaging platform developed its activities to propose new services.
IMAPPI (Integrated Magnetic resonance and PET in preclinical imaging)
This project is a 7.3M€ founded Equipex which aim is to develop a preclinical PET-MRI prototype together with specifi c molecular probes and experimental models. This public – private partnership combines expertises from Bioscan, CGFL, Burgundy university molecular chemistry institute, Multidisciplinary laboratory Carnot from Bourgogne, Besançon UTINAM institute, Dijon teaching hospital, Le2i, Welience, Oncodesign, NVH Medicinal and Chematech.
We have developed strong local partnerships to propose a unique and complete set of competences in two main areas: Biomolecule development (Engicare) and Pharmaco-imaging (PharmImage). These partnerships offer a strong competitive advantage with unifi ed study processes in complementary domains, keeping a high-level of knowledge, expertise, and capabilities.
New authorized radionuclides
To develop its activities, additional radionuclides are now authorized:
- PET imaging: 18F, 64Cu, 68Ga, 89Zr, 124I;
- therapy: 67Cu, 186Re, 188Re, 177Lu.
New imaging modalities: PET / CT – MRI (Positron Emission Tomography / Computed Tomography – Magnetic Resonance Imaging)
To complete NanoSPECT-CT imaging system (Single Photon Emission Tomography / Computed Tomography, Bioscan), CGFL preclinical imaging platform is now equipped with a BioPET-CT system (Bioscan) associating last-generation PET detection (phoswich LYSO / GSO) and high resolution CT imaging. This sytem is coupled to a MRS 3000 MRI with a 3 Tesla magnet and compatible with Minerve beds used on NanoSPECT-CT and BioPET-CT imaging system.
It is now possible to register nuclear imaging with magnetic imaging. Moreover, at the end of the IMAPPI project, PET / MR acquisitions will be simultaneous.
Summary of main imaging endpoints per therapeutic area:
Additional assays could be performed upon demand.